SCOTTSDALE, Ariz., Dec. 4 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for T2 diabetes therapies.
In this report, entitled "MedPredict Thought Leader Insight & Analysis: T2 Diabetes," physician experts discuss the interplay between diabetes and cardiovascular disease.
"Recent changes to the American Diabetes Association guidelines
highlight the diabetic's increased risk for coronary artery disease (CAD),"
according to MedPredict's President Jeff Berk. "In light of these
guidelines, our Panel provides insight into unmet needs and the
endocrinologist's emerging therapeutic management strategies for diabetes,
CAD, metabolic syndrome and nonalcoholic steatohepatitis (NASH)."
-- Incretins will dominate new launches for HbA1c lowering drugs for the
next few years. The Panel discusses the significance of targeting
DPP4, DPP8 and DPP9, and compares this class with GLP-1 agonists.
Strengths and weaknesses of new monotherapies and combination
approaches are discussed.
-- These new orals and parenterals will put pressure on established
products, including metformin, sulfonylureas and TZDs. The Panel
offers insight into how each fits into the diabetes / CAD paradigm.
-- The Panel describes why Exubera has failed commercially, and
benchmarks next-generation insulins.
-- While still very early in development, the Panel shared key insights
about the future for inhibition of SGLT.
Key products mentioned in this report: metformin, Januvia/Janumet (sitagliptin; Merck), Byetta (exenatide; Lilly/Amylin), exenatide LAR (Lilly/Amylin/Alkermes), Symlin (Amylin), pramlintide + leptin (Amylin/Amgen), Galvus (vildagliptin; Novartis), alogliptin (Takeda), saxagliptin (BMS/AZ), Redona (denagliptin; GSK), liraglutide (Novo Nordisk), Boc5 (UC Riverside / Chinese Acad. Sci.), substituted quinoxalines (Pfizer/Novo Nordisk), Actos (pioglitazone; Takeda/Lilly), Avandia (rosiglitazone; GSK), Exubera (Nektar), AIR Insulin (Lilly/Alkermes), Technosphere (Mannkind), AERx (Novo Nordisk/Aradigm), Oral-lyn (Generex/Lilly), buccal insulin (GSK).
This report can be purchased by contacting MedPredict. Members of the media may request an interview.
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
Copyright©2007 PR Newswire.
All rights reserved